Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Stop IBS
- Development stage
- Unknown
- Lead developer
- Charak
- Administration
- Oral
01
Overview
Stop IBS is an Ayurvedic proprietary formulation developed and marketed by Charak for the management of irritable bowel syndrome (IBS). It is composed of a blend of traditional Ayurvedic herbs, including Kutaj (Holarrhena antidysenterica), Bilva (Aegle marmelos), Brahmi (Bacopa monnieri), and Sunthi (Zingiber officinale). The formulation is designed to regulate gut motility, normalize stool frequency and consistency, reduce intestinal inflammation, and alleviate symptoms such as abdominal pain, bloating, flatulence, and cramping.
- Brand names
- Stop IBSStop IBS TabletsStop-IBSStop-IBS Tablets
- Other names
- Stop IBS TabletStop-IBS Tablet
Beyond the preview
Go deeper on Stop IBS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stop IBS.